XML 33 R18.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Stock-Based Compensation | 12 Months Ended
--- | ---
Dec. 31, 2023
Share-Based Payment Arrangement [Abstract] |
Stock-Based Compensation | Note 10 – Stock-Based Compensation Stock Incentive Plans The Company’s board of directors adopted, and shareholders approved, the Co-Diagnostics, Inc. Amended and Restated 2015 Long Term Incentive Plan (the “Incentive Plan”) providing for the issuance of stock-based incentive awards to employees, officers, consultants, directors and independent contractors. On August 31, 2022 the shareholders approved an increase in the number of awards available for issuance under the Incentive Plan to an aggregate of 12,000,000 shares of common stock. The number of awards available for issuance under the Incentive Plan was 4,357,937 at December 31, 2023. Stock Options The following table summarizes option activity during the years ended December 31, 2023 and 2022: Schedule of Option Activity
|  | Number of Options |  |  | Weighted Average Exercise Price |  |  | Weighted Average Fair Value |  |  | Weighted Average Remaining Contractual Life (Years) |
Outstanding at December 31, 2021 |  |  | 1,111,363 |  |  | $ | 2.12 |  |  | $ | 1.31 |  |  |  |  |
Granted |  |  | - |  |  |  | - |  |  |  | - |  |  |  |  |
Expired |  |  | - |  |  |  | - |  |  |  | - |  |  |  |  |
Forfeited/Cancelled |  |  | - |  |  |  | - |  |  |  | - |  |  |  |  |
Exercised |  |  | (70,791 | ) |  |  | 1.10 |  |  |  | 0.51 |  |  |  |  |
Outstanding at December 31, 2022 |  |  | 1,040,572 |  |  | $ | 2.19 |  |  | $ | 1.37 |  |  |  | 5.88 |
Granted |  |  | - |  |  |  | - |  |  |  | - |  |  |  |  |
Expired |  |  | - |  |  |  | - |  |  |  | - |  |  |  |  |
Forfeited/Cancelled |  |  | - |  |  |  | - |  |  |  | - |  |  |  |  |
Exercised |  |  | - |  |  |  | - |  |  |  | - |  |  |  |  |
Outstanding at December 31, 2023 |  |  | 1,040,572 |  |  | $ | 2.19 |  |  | $ | 1.37 |  |  |  | 4.89 |
Exercisable at December 31, 2023 |  |  | 1,040,572 |  |  | $ | 2.19 |  |  | $ | 1.37 |  |  |  | 4.89 |
The total intrinsic value of options exercised during the years ended December 31, 2023 and 2022, respectively, was $0 and approximately $0.4 million. The aggregate intrinsic value of outstanding options at December 31, 2023 and 2022 was approximately $0.2 million and $0.8 million, respectively. As of December 31, 2023, there were no unvested options and no unrecognized stock-based compensation expense related to options. Restricted Stock Units The grant date fair value of RSUs granted is determined using the closing market price of the Company’s common stock on the grant date with the associated compensation expense amortized over the vesting period of the awards. The following table sets forth the outstanding RSUs and related activity for the years ended December 31, 2023 and 2022: Schedule of Outstanding Restricted Stock Units and Related Party
|  | Number of RSUs |  |  | Weighted Average Grant Date Fair Value |
Unvested at December 31, 2021 |  |  | 1,267,415 |  |  | $ | 9.94 |
Granted |  |  | 1,925,476 |  |  |  | 5.66 |
Vested |  |  | (725,166 | ) |  |  | 8.66 |
Forfeited/Cancelled |  |  | (41,000 | ) |  |  | 8.31 |
Unvested at December 31, 2022 |  |  | 2,426,725 |  |  | $ | 6.95 |
Granted |  |  | 1,948,750 |  |  |  | 1.92 |
Vested |  |  | (1,354,081 | ) |  |  | 6.17 |
Forfeited/Cancelled |  |  | (95,897 | ) |  |  | 6.16 |
Unvested at December 31, 2023 |  |  | 2,925,497 |  |  | $ | 3.99 |
As of December 31, 2023, there was $9.5 million of unrecognized stock-based compensation expense related to outstanding RSUs which is expected to be recognized over a weighted-average period of 1.7 years. Warrants The Company has issued warrants related to financings, acquisitions and as compensation to third parties for services provided. The Company estimates the fair value of issued warrants on the date of issuance as determined using a Black-Scholes pricing model. The Company amortizes the fair value of issued warrants using a vesting schedule based on the terms and conditions of each warrant if granted for services. The following table summarizes warrant activity during the years ended December 31, 2023 and 2022: Schedule of Warrant Activity
|  | Number of Warrants |  |  | Weighted Average Exercise Price |  |  | Weighted Average Fair Value |  |  | Weighted Average Remaining Contractual Life (Years) |
Outstanding at December 31, 2021 |  |  | 526,281 |  |  | $ | 8.15 |  |  | $ | 4.01 |  |  |  | 4.7 |
Issued for adjustments to contingent purchase consideration |  |  | 8,719 |  |  |  | 9.13 |  |  |  | 1.88 |  |  |  |  |
Granted |  |  | - |  |  |  | - |  |  |  | - |  |  |  |  |
Expired |  |  | - |  |  |  | - |  |  |  | - |  |  |  |  |
Forfeited/Cancelled |  |  | - |  |  |  | - |  |  |  | - |  |  |  |  |
Exercised |  |  | (50,000 | ) |  |  | 2.00 |  |  |  | 1.22 |  |  |  |  |
Outstanding at December 31, 2022 |  |  | 485,000 |  |  | $ | 8.81 |  |  | $ | 2.43 |  |  |  | 4.0 |
Granted |  |  | - |  |  |  | - |  |  |  | - |  |  |  |  |
Expired |  |  | - |  |  |  | - |  |  |  | - |  |  |  |  |
Forfeited/Cancelled |  |  | - |  |  |  | - |  |  |  | - |  |  |  |  |
Exercised |  |  | - |  |  |  | - |  |  |  | - |  |  |  |  |
Outstanding at December 31, 2023 |  |  | 485,000 |  |  | $ | 8.81 |  |  | $ | 1.29 |  |  |  | 3.0 |
The intrinsic value of warrants exercised during the years ended December 31, 2023 and 2022, respectively, was $0 and approximately $0.3 million. The aggregate intrinsic value of outstanding warrants at December 31, 2023 was approximately $0. The total number of warrants exercisable at December 31, 2023 is 20,000. The ability to exercise the approximately 465,000 warrants issued in connection with acquisitions in prior years is contingent upon the achievement of certain development and revenue milestones on or before January 1, 2027. There was no unrecognized stock-based compensation expense related to warrants. Stock-Based Compensation Expense The Company recognized stock-based compensation expense as follows: Schedule of Recognized Stock-based Compensation Expense
|  | 2023 |  |  | 2022 |
|  | Years Ended December 31, |
|  | 2023 |  |  | 2022 |
Cost of sales |  | $ | 46,586 |  |  | $ | 63,058 |
Sales and marketing |  |  | 2,153,974 |  |  |  | 1,866,116 |
General and administrative |  |  | 4,933,822 |  |  |  | 4,050,967 |
Research and development |  |  | 1,202,473 |  |  |  | 1,563,082 |
Total stock-based compensation expense |  | $ | 8,336,855 |  |  | $ | 7,543,223 |

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration